The catabolism of retinoic acid (RA) is an essential mechanism for restricting the exposure of specific tissues and cells to RA. We recently reported the identification of a RA-inducible cytochrome P450 [P450RAI(CYP26)], in zebrafish, mouse, and human, which was shown to be responsible for RA catabolism. P450RAI exhibits a complex spatiotemporal pattern of expression during development and is highly inducible by exogenous RA treatment in certain tissues and cell lines. Sequence analysis of the proximal upstream region of the P450RAI promoter revealed a high degree of conservation between zebrafish, mouse, and human. This region of the promoter contains a canonical retinoic acid response element (5-AGT-TCA-(n) 5 -AGTTCA-3), embedded within a 32-bp region (designated R1), which is conserved among all three species. Electrophoretic mobility shift assays using this element demonstrated the specific binding of murine retinoic acid receptor-␥ (RAR␥) and retinoid X receptor-␣ (RXR␣) proteins. Transient transfection experiments with the mouse P450RAI promoter fused to a luciferase reporter gene showed transcriptional activation in the presence of RA in HeLa, Cos-1, and F9 wild-type cells. This activation, as well as basal promoter activity, was abolished upon mutation of the RARE. Deletion and mutational analyses of the P450RAI promoter, as well as DNase I footprinting studies, revealed potential binding sites for several other proteins in conserved regions of the promoter. Also, two conserved 5-TAAT-3 sequences flanking the RARE were investigated for their potential importance in P450RAI promoter activity. Moreover, these studies revealed an essential requirement for a G-rich element (designated GGRE), located just upstream of the RARE, for RA inducibility. This element was demonstrated to form complexes with Sp1 and Sp3 using nuclear extracts from either murine F9 or P19 cells. Together, these results indicate that the P450RAI-RARE is atypical in that conserved flanking sequences may play a very important role in regulating RA inducibility and expression of P450RAI(CYP26). (Molec-
INTRODUCTION
Retinoic Acid (RA), the principal active metabolite of vitamin A, is an essential regulator of pattern formation during embryonic development and is necessary for the maintenance of epithelial tissues in the adult (1) (2) (3) . The activity of RA is determined by several parameters including those that influence receptor activity and those that govern ligand availability. In this regard, the effects of RA on gene expression are principally mediated by two families of retinoid nuclear receptors comprised of three subtypes each; retinoic acid receptors (RARs ␣, ␤, and ␥) and, retinoid X receptors (RXRs ␣, ␤, and ␥) (4). RARs and RXRs commonly participate together, in the form of heterodimers, to regulate transcription (5, 6) . Most tissues, especially during embryonic development, express one or more of the RAR and RXR subtypes in various combinations possibly giving rise to different responses to RA (7, 8) .
Retinoic acid response elements (RAREs) exist in various forms and can also influence receptor activity. Typically, a RARE is comprised of two direct repeats of the motif, 5Ј-PuGTTCA-3Ј separated by a 5-bp spacer; however, various other polymorphic forms of RAREs have been characterized, having 1-or 2-bp spacers. Several studies suggest that specific forms of RAREs may preferentially bind different heterodimeric RAR/RXR pairs (9) .
The active forms of RA include all-trans RA, and 9-cis RA stereoisomers, which are ligands for these receptors; RARs are activated by both isoforms while RXRs appear to be activated exclusively by 9-cis RA. It is not clear at present how interconversion between the two forms is controlled; however, the balance of all-trans RA and 9-cis RA may be important for RA activity. The distribution of RA is also a critical determinant in the regulation of RA responsive genes, especially in developing tissues. There is growing evidence that tight spatial and temporal control of RA synthesis and catabolism are important in establishing regional distribution patterns of RA (10) (11) (12) (13) (14) .
Control of RA tissue distribution is thought to be established by the balanced expression of RA synthesizing and RA catabolizing enzymes. Several retinaldehyde dehydrogenases have already been implicated in the irreversible conversion of retinaldehyde to the active RA (10, 11) . Retinaldehyde dehydrogenase type 2 (RALDH-2) is thought to be a key enzyme in localized production of RA during embryogenesis since it exhibits an expression pattern consistent with that of a retinoid-responsive LacZ reporter transgene. Moreover, RALDH-2 knockout mice have severe developmental defects and die at midgestation; however, knockout embryos are rescued when the mother is treated with RA (12) (13) (14) .
The metabolism of RA is initiated by hydroxylation (15) mediated by cytochrome P450 activity, as judged by the ability of broad spectrum P450 inhibitors such as ketoconazole and liarozole to block 4-hydroxylation (16) (17) (18) (19) (20) . In certain tissues, including testis, skin, and lung and in numerous cell lines, such as NIH3T3 fibroblasts, HL60 myelomonocytic leukemic cells, F9 and P19 murine embryonal carcinoma cells, MCF7 human breast cancer cells, and HeLa human cervix cancer cells, RA metabolism can be induced by RA treatment (20) (21) (22) (23) .
P450RAI(CYP26) is a cytochrome P450 enzyme that specifically metabolizes RA and is likely responsible for much of the RA-inducible RA metabolism observed. P450RAI was first isolated from zebrafish as a gene product induced by RA during regeneration of adult caudal fin (24) . Subsequently, homologs have been isolated from human (25) , mouse (26) , chick (27) , and Xenopus (28) with all the genes exhibiting a high degree of sequence conservation. P450RAI metabolizes all-trans RA but not the 9-cis or 13-cis RA isomers (24, (29) (30) (31) (32) (33) (34) . Previous studies demonstrated that P450RAI expression is strongly induced by RA in early mouse and Xenopus embryos as well as in a number of normal and tumor cell lines. Several studies have examined the spatiotemporal expression of P450RAI during embryonic development (28, (35) (36) (37) (38) . Primary sites of P450RAI expression in mouse include neural folds before neural tube closure, and caudal neural epithelium, although most tissues at various stages of morphogenesis transiently express P450RAI (35) (36) (37) . Studies in mouse and Xenopus have shown that P450RAI expression generates domains restricting RA exposure (36, 38) , possibly resulting in differential rates or timing of differentiation. In several cases it would appear that P450RAI and RALDH-2 expression are complementary, possibly forming boundaries defined by graded retinoic acid distribution between RA synthesizing regions and RA degrading regions (28, 38) .
The focus of our work, guided by the sequence conservation between human, mouse, and zebrafish in the upstream proximal promoter, was to characterize elements necessary for RA induction and regulation. We show that a conserved RARE and a Sp1/Sp3 binding site are essential for the RA-regulated induction of P450RAI (39) (40) (41) (42) .
RESULTS

Human, Mouse, and Zebrafish Promoter Alignment
Sequences of genomic P450RAI clones isolated from human, mouse, and zebrafish were aligned using GeneWorks 2.0. This analysis revealed extensive conservation in the intron/exon boundaries as well as striking regions of conservation in the 5Ј-flanking region (25, 42) . A particularly high degree of homology was observed between mouse and human promoter sequences with distinct motifs conserved among all three species (Fig. 1A) . Of particular note, each promoter contains a direct repeat of the sequence TGAACT separated by five spacer nucleotides characteristic of a canonical retinoic acid response element (RARE-DR5). This DR5 is embedded within a 32-bp region that, with the exception of one nucleotide, is perfectly conserved between zebrafish, mouse, and human (designated R1). The P450RAI-RAREs were then aligned with different known RAREs (Fig. 1B) . It is interesting to note the similarity between P450RAI-RAREs, RAR␤2-RAREs, and Hoxa-1-RAREs, in particular with respect to the spacer nucleotides. The significance of this conservation is not yet known. In the mouse promoter, 39 bp downstream of this R1 region, is a putative TATA box (represented as a TATAA motif in all three species) which is upstream of the transcription start site, previously identified by S1 nuclease mapping (32) . While other regions of the P450RAI promoter are less well conserved, several smaller GC-rich elements can be identified upstream of this R1 region. The closest upstream region is a guanine-guanine-rich element (designated GGRE) perfectly conserved in mouse and human sequences, with the exception of one nucleotide for the zebrafish sequence. This G-rich element in the zebrafish (GGGCGG) can be identified as a putative Sp1 recognition site (Fig. 1A) (43) .
Characterization of a Retinoic Acid Response Element (RARE) in the P450RAI Promoter
To demonstrate that the putative RARE in the P450RAI promoter is a target for retinoic acid receptors and to confirm our previous findings implicating the involvement of RAR␥ and RXR␣ (26), we performed bandshift experiments with in vitro transcribed and translated mouse RAR␥ and RXR␣ proteins. Oligonucleotides ( Fig. 2A) corresponding to the R1 wild-type (WT) and mutated (MT) region that contains the P450RAI-RARE were analyzed in gel mobility shift assays (Fig. 2B) . No protein/oligonucleotide complexes are observed in the lysate control lane (lane 1) and the presence of individual RAR␥ or RXR␣ proteins is insufficient to produce a shift in mobility (lanes 1-3) . The addition of both A, The starting ATG codon (M for methionine), the putative TATA box, the R1 region, and the G-rich element (GGRE) are boxed. The consensus sequence of the RARs are included in the R1 region, marked by two arrows, indicating their orientation and shadowed in gray to show their conservation between the three species. Bars between human, mouse, and zebrafish sequences indicate identity, 87% for human and mouse, and 51% for mouse and zebrafish. B, RAREs (DR5) from other promoters (gene and organism described) were aligned with the P450RAI-RAREs. All the direct repeats are boxed, and the sequence homology is shown in light gray. The dark gray areas show the homology in the surrounding nucleotides.
RAR␥ and RXR␣ proteins in combination produced a strong complex characteristic of a typical RARE (lane 4). Conversely, mutations in the RARE half-sites (lanes 5-8) ablated the formation of this complex in the presence of both in vitro translated RAR␥ and RXR␣ proteins. A, The oligonucleotides used in these experiments are shown, and the mutation performed in the direct repeats (in light gray) of the R1-RARE are marked by asterisks. B, Migration of the R1-WT and R1-MT was performed on a 6% nondenaturing polyacrylamide gel (PAGE), without, with one, or with both RAR␥ and RXR␣ nuclear receptors. C, The experiments using the nuclear extracts of P19 teratocarcinomal, F9 wild-type, and F9 RAR␥ Ϫ/Ϫ RXR␣ Ϫ/Ϫ cells were performed on a 6% nondenaturing PAGE. Different complexes (C1-C4) are distinguishable on the gel and are shown by arrows. The RXR supershifts are indicated on the top right of the F9 wild-type and P19 panels. Similar R1 oligonucleotides were tested using crude nuclear extracts from P19, F9 wild-type teratocarcinoma cells and F9 cells in which the RAR␥ and RXR␣ genes had been ablated by homologous recombination (Fig. 2C) 
Transcriptional Activity of the Proximal Region of the P450RAI Promoter
To investigate the transcriptional activity of the mouse P450RAI promoter and the putative RARE activity, we used cotransfection assays. The mouse P450RAI-RARE and its flanking sequences were mutated as shown in Fig. 3A . A 256-bp fragment of the wild-type or mutated mouse P450RAI promoter was amplified and subcloned into a pGL3 basic luciferase reporter vector (Fig. 3A ). Cells were transfected with the wildtype promoter construct (P450RAI-WT) along with various amounts of expression vectors for mouse RAR␥ and RXR␣, encoding receptors previously shown to be necessary for P450RAI induction by RA (26) . Depending on the amount of both RAR␥ and RXR␣ receptors added, the transcriptional activity of P450RAI-WT promoter increased. These analyses allowed for the optimization of the amount of receptors required (0.2 g of RAR␥ and 0.2 g of RXR␣). Using these promoter constructs we compared proximal promoter activities in the F9 wild-type and F9 RAR␥ Ϫ/Ϫ RXR␣ Ϫ/Ϫ double knockout cell lines. When the P450RAI promoter was transfected alone into F9 wild-type cells, addition of 10 Ϫ6 M all-trans RA resulted in a 2-fold marked increase in transcriptional activity (See Fig. 3B , P450RAI-WT, left panel). While some inducible promoter activity can be measured in the F9 mutant cell line, the absolute levels of activity are much lower (Fig.  3B , P450RAI-WT, right panel). By comparison, both wild-type and mutant F9 cell lines support similar levels of transcriptional activity, when the promoter construct was cotransfected with expression plasmids for RAR␥ and RXR␣ (Fig. 3B , P450RAI-WT, compare left and right panels). Similarly, mutations in the R1-RARE abolish RA-inducible activity, and cotransfection of both RAR␥ and RXR␣ does not compensate for this lost activity (Fig. 3B , P450RAI-RARE-mut, left and right panels). Also, transfection of the wild-type promoter construct (P450RAI-WT) in the presence of RA, in Cos-1 and HeLa cells, shows a 3-fold increase in activity in comparison with the nontreated cells (Fig.  3C , Cos-1 and HeLa). Addition of RAR␥ and RXR␣ to the transfection mix increased the transcriptional activity by 2-fold without RA, likely due to residual RA activity in the culture media. In the presence of both receptors and 10 Ϫ6 M all-trans RA, the transcriptional activity increased by 4-fold in HeLa and 5-fold in Cos-1. The putative RARE located in the R1 region was mutated, to the MT sequence (Fig. 3C , P450RAI-RARE-mut). Transient transfection analyses of P450RAI-RARE-mut revealed a complete ablation of the retinoic acid response, in the absence or in the presence of receptors (Fig. 3C ). This complete loss of retinoic acid induction indicated that the mutation of the direct repeat located in R1 ablated the functional activity of this P450RAI-RARE.
Analysis of TAAT Motif Contributions to P450RAI Transcriptional Activity
The striking degree of conservation around the R1-RARE prompted us to examine the contribution of flanking regions for their influence on the transcriptional activity of this RARE. Inspection of the RARE flanking sequences revealed that the 5Ј-and the 3Ј-regions were similar in that they contain conserved 5Ј-TAAT-3Ј elements (Fig. 3A) . This characteristic element has previously been demonstrated to form the core recognition element for homeobox proteins in other promoters (45) (46) (47) . Interestingly, introducing a change from 5Ј-TAAT-3Ј (or "ATTA" on the upper coding strand) to a 5Ј-TACT-3Ј (Fig. 3A , P450RAI-5Ј-TAAT-mut) resulted in a dramatic drop in basal transcriptional activity, as well as a loss of 90% of the RA response upon mutation of the 5Ј-motif (Fig. 3C , P450RAI-5Ј-TAAT-mut, Cos-1 and HeLa). This would suggest that the conserved 5Ј-TAAT-3Ј motif in 5Ј of the RARE has a positive influence on the RARE activity. In contrast, introducing the same change in the 3Ј-motif (Fig. 3A , P450RAI-3Ј-TAAT-mut), resulted in an enhanced RA response in the case of HeLa cells transient transfections, approximately 2-fold in the presence of RA, with or without added receptors (Fig.  3C , P450RAI-3Ј-TAAT-mut, HeLa). No significant change in reporter gene activity in comparison with the wild-type promoter was observed in the case of Cos-1 cell transient transfections (Fig. 3C , P450RAI-3Ј-TAAT-mut, Cos-1). These results suggest that there may be cell-specific factors influencing P450RAI transcription through the R1 region.
Determination of Protein/DNA Interactions by DNase I Footprinting Analysis
To visualize protein/DNA contacts around the RARE and the rest of the proximal P450RAI promoter, we performed in vitro DNase I footprinting analyses. We used murine liver extracts for this study since P450RAI was expressed and could be up-regulated by RA treatment (32) . Total RNA was extracted from liver tissue obtained from mice treated for 2, 8, and 24 h with 100 mg/kg all-trans retinoic acid and analyzed by Northern blotting. We observed that the P450RAI transcript was expressed at low levels even in untreated animals (Fig. 4A, lane 4) and was strongly induced by exposure to exogenous RA (lane 1-3). Fig 4B shows the DNase I footprint experiment with increasing concentrations of liver nuclear extracts with the P450RAI coding strand encompassing sequences between Ϫ170 and Ϫ80. Liver extracts from untreated mice were used since no significant differences in footprint patterns were observed in liver extracts from RAtreated and untreated mice (data not shown). Two major areas of protection from DNase I were evident even at low protein extract concentrations. One region of protection was coincident with the RAR/RXR protein complex binding site between Ϫ120 and Ϫ95. A second strong area of protection was observed upstream of the R1 element between Ϫ156 and Ϫ137, surrounding the annotated GGRE. Areas of DNase I hypersensitivity (indicated by arrows) flank both of these protected regions. Figure 4C shows the DNase I footprints obtained for both the coding and the noncoding strands of P450RAI from Ϫ238 to Ϫ60. An additional but less distinct area of protection was observed between Ϫ81 and Ϫ70 and several areas of hypersensitivity were evident in the proximal promoter region. At present, we do not know the nature of the factors influencing DNase I sensitivity at these sites. Interestingly, areas of protection and hypersensitivity are consistent for both the coding and the noncoding strands (Fig. 4C , both panels). Results for both strands are summarized in Fig. 4D .
An Upstream G-Rich Element Supports RARE Activity
The appearance of a strong DNase I footprint upstream of the R1 element (GGRE) led us to further analyze this region by transient transfection experiments. When nucleotides from Ϫ238 to Ϫ137 were deleted (Fig. 5A, P450RAI-137 ), the activity of the promoter was reduced by 40% (nontreated) to 85% (RA treated) in HeLa cells when compared with the wildtype promoter (P450RAI-WT) and was negligible in Cos-1 and F9 wild-type cells (Fig. 5B) . Interestingly, the P450RAI-137 construct, when cotransfected with both retinoic acid receptors RAR␥ and RXR␣, in the presence of RA, did not give rise to RA inducibility. An extended construct encompassing the GGRE (Fig. 5A , P450RAI-163) restored the RA inducibility of the promoter and approximately 25% (nontreated) to 50% (RA treated) of the transcriptional activity of the wildtype promoter (P450RAI-WT) in all three cell lines (Fig.  5B , HeLa, Cos-1, and F9WT). All constructs containing both the GGRE and the RARE had similar levels of inducibility by RA treatment although absolute levels of luciferase activity were different (Fig. 5B , HeLa, Cos-1, and F9WT). Inclusion of the sequences between Ϫ238 and Ϫ163 further increased the activity of the promoter, demonstrating the requirement of upstream regions for the full restoration of the activity of the promoter. These results suggest that the RA response mediated through the P450RAI-RARE is dependent on direct or indirect interactions with upstream sequences, which include the GGRE.
Sp1/Sp3 Transcription Factors Interact with the GGRE Element in Vitro
The DNase I footprint analyses and the transient transfection data suggest that the GGRE is an important regulator of the P450RAI promoter activity. Gel mobility shift assays were performed using probes encompassing the nucleotides Ϫ163 to Ϫ137, named GGRE-WT for the wild-type and GGRE-MT for the mutated form (Fig. 6A) , with nuclear extracts from the murine F9 (Fig. 6B ) and P19 (Fig. 6C ) teratocarcinoma cell lines. Two strong complexes ( Fig. 6A and 6B, complexes A and B) were observed in both cell lines. The G-rich nature of this element and the configuration of the complexes formed implied that this element bound Sp1 and Sp3 proteins. Moreover, very similar complexes were observed using the same extracts, with oligonucleotides containing a Sp1 consensus site (Fig. 6A) . To determine whether Sp1/Sp3 proteins were involved, Sp1 and Sp3 affinity-purified polyclonal antibodies were used in supershift assays. Anti-Sp1-specific antibodies reduced the appearance of complex A and a supershift was observed (Fig. 6 , B and C, see Sp1 supershift) with both CSp1 (compare lanes 5 and 8) and GGRE-WT (compare lanes 6 and 9) oligonucleotides. Complex B (Fig. 6 , B and C) remained unchanged. Conversely, the anti-Sp3 antibodies essentially eliminated complex B and formed a supershift in the case of both probes (CSp1 and GCRE) using either F9 or P19 nuclear extracts. To localize the binding site of both Sp1 and Sp3 on GGRE-WT, we generated a mutation in the core guanine-rich region, from GGGGGG (Ϫ154 to Ϫ149) to GCATCG (Fig. 6A) . By mutating the guanine-rich region, we totally ablated Sp1/Sp3 complex formation (Fig. 6 , B and 6C; lane 15), as expected. A third complex (complex C), however, was not sensitive to the mutation in the GGRE. Together, these results indicate that Sp1/Sp3 proteins are able to complex with the GGRE region, in the guanine-rich region, and participate in the retinoic acid response by interacting directly or indirectly with proteins binding to the R1-RARE.
DISCUSSION
P450RAI is an important regulator of RA distribution during development. The analysis of its expression in mouse, chick, and Xenopus embryos revealed complex, stage-specific patterns possibly reflecting a role for this enzyme in limiting tissue exposure to RA (28, (35) (36) (37) (38) 48) . Moreover, analysis of P450RAI expression in cultured human cells shows that exogenous RA can strongly induce the expression of this gene (34) . In our present study, we show that at least some of the RA inducibility of P450RAI is due to regulation at the transcriptional level, mediated by a highly conserved RARE. Furthermore, we determined the presence of other response elements, associated with the P450RAI-RARE, that may be important contributors in establishing complex stage-specific patterns of P450RAI expression.
Analysis of human, mouse, and zebrafish proximal regions of the P450RAI promoter allowed us to determine the presence of a canonical RARE within a conserved 32-bp sequence, which was shown to be recognized by the RAR␥/RXR␣ heterodimer, consistent with our previous findings demonstrating that exogenous all-trans RA induction of P450RAI mRNA in F9 cells is mediated by RAR␥ and RXR␣ (26) . A comparison of this P450RAI-RARE with other RAREs such as the murine RAR␤2-RARE and Hoxa-1-RARE reveals similarity even within the spacer nucleotides (Fig. 3B) . Whether this reflects a subtle functional role for the spacer region remains to be determined. In addition, transfection experiments with wild-type and mutated promoters confirmed that the RA inducibility was dependent on the presence of the RARE motif. The P450RAI promoter was shown to be responsive to RA in HeLa, Cos-1, and F9 wild-type cells. However, expression of the endogenous P450RAI gene is not detected in Cos-1 cells treated with RA (data not shown), indicating that additional elements in the P450RAI promoter, not included in the constructs used in these experiments, are important in the regulation of its expression. Because the pattern of expression of P450RAI during embryogenesis is highly spatiotemporally regulated, we speculated that homeodomain proteins might be involved in the control of the transcriptional activity of P450RAI. Interestingly, this R1 region also contained two conserved 5Ј-TAAT-3Ј motifs flanking the RARE; such motifs are generally found in homeodomain factor DNA binding sites (45) (46) (47) . Both DNase I footprint analyses and transient transfections suggest the presence of factor(s) binding either the 5Ј-or the 3Ј-conserved TAAT elements. Bandshift assays using 5Ј-and 3Ј-TAAT mutants within the R1 region, however, did not reveal obvious differences in DNA binding patterns (data not shown). The importance of these elements in the control of P450RAI activity, and whether or not Hox or related genes interact with this sequence, remains to be determined.
An unexpected observation in these studies came from the apparent dependence of the RARE activity on the presence of upstream regulatory sites, including an Sp1/Sp3 binding site. DNase I footprint analyses revealed the proximity of both sites, and transient transfections confirmed the requirement of the Sp1/ Sp3 binding site for RA response. Sp1 activity has been shown previously to be essential for the activity of adjacent response elements in other promoters. For example, cooperativity between the sterol-regulatory element and Sp1 was observed in transcriptional regulation of the low-density lipoprotein (LDL) receptor gene promoter (49) . Similarly, apparent physical interactions between the estrogen receptor (ER) and Sp1 appear to be required for the enhanced transactivation of the heat-shock protein 27 (Hsp27) promoter gene (50) . Complex interactions between the orphan nuclear receptor ␣ (ROR␣) and Sp1 were also proposed in the promoter regulation of the murine prosaposin gene (51) . Also, multiple Sp1 sites have been identified adjacent to the RARE in the retinoic acid receptor ␥ isoform 2 (RAR␥2) promoter gene. RAR/Sp1 cotransfection experiments suggest interdependence between Sp1 and RAR/RXR activities (52) . While it would appear that Sp1 and RARs could participate together in the regulation of several different promoters, the nature of these interactions remains to be explored.
Murine F9 and P19 cell lines are able to express P450RAI after RA treatment (26) . By using nuclear extracts from these cell lines, we also identified the binding to the GGRE of Sp3, another transcription factor member of the C 2 -H 2 zinc-finger family. Mutations in the GGRE ablate the binding of both Sp1 and Sp3 in gel shift mobility assays. Previous studies have demonstrated that Sp1 and Sp3 can bind to the same site with comparable affinity (53) . Sp1 and Sp3 have been shown to be bifunctional, acting either as activators or as repressors (39, 41, 44, 54, 55) . Considering the expression of Sp1 and Sp3, their degree of phosphorylation, and their potential interaction with other factors, we hypothesize that the regulation of P450RAI may be modulated by signaling pathways that directly affect Sp1/Sp3 abundance and activity.
In vivo, there is a strong overlap between the expression of RALDH-2 and that of a RA reporter gene comprising a RAR␤-RARE linked to a ␤-galactosidase gene (56) These findings imply that where RALDH-2 is expressed, free RA is generated to regulate RA responsive genes such as RAR␤. Interestingly RALDH-2 and P450RAI domains of expression are often complementary (27, 38) . This suggests that the RA responsiveness of P450RAI can be controlled by other factors in a tissue-or a domain-specific manner. Consistent with this, we have previously shown that certain cell lines do not express P450RAI even in the presence of RA, while others express P450RAI in an apparent constitutive manner, possibly indicating the involvement of factors capable of overriding RA control (31) .
In summary, analysis of the mouse P450RAI promoter revealed the presence of a highly conserved RARE whose activity depends on an upstream Sp1/ Sp3 element. Interestingly, Sp1 is an essential factor for normal embryogenesis (57) . Furthermore, the presence of several conserved elements including possible homeodomain protein binding sites may help to explain how the complex spatio-temporal patterns of P450RAI expression are generated during embryogenesis. 
MATERIALS AND METHODS
Isolation of the Zebrafish, Mouse, and Human Promoter Sequences
The zebrafish P450RAI(CYP26) gene was first isolated from a zebrafish genomic library (30, 42) . Mouse genomic clones were isolated by screening 10 6 plaques of a mouse genomic library with the mouse P450RAI cDNA probe (mouse genomic library 129SV, generously donated by Dr. Janet Rossant). Sequencing of the 5Ј-region of the genomic DNA allowed for the identification of the promoter region. Human genomic clones were obtained from the Canadian Genome Analysis and Technology Program by screening a P1-artificial chromosome library with human P450RAI cDNA. Four individual PAC clones (245C7, 48I5, 223I8, and 250L19) encompassing the human P450RAI(CYP26) gene were characterized. PAC 245C7 was selected for analysis of the 5Ј-promoter region. Sequence analyses were performed using the GeneWorks (Intellegenetics, Inc., Mountain View, CA) software package.
DNA Plasmids
The reporter plasmids contain different segments or mutants of a minimal upstream region of the mouse P450RAI cloned in the pGL3 luciferase reporter vector (Promega Corp., Madison, WI).
The P450RAI-WT, Ϫ163, and Ϫ137 constructs were generated by PCR amplification (30 cycles) of the upstream region (nucleotides Ϫ238 to ϩ18) of the mouse P450RAI promoter, using the forward primers, P450RAI-WT, 5Ј-CCA-GATCTGCGCGCTCAGAGGGAAGCCGC-3Ј; P450RAI-163, 5Ј-GATCAGAT CTGCGCCTCGAGGGGGGAGGAGCCAGG-3Ј; P450RAI-137, 5Ј-GATCAGATCT GCCCGATCCGCAAT-TAAAGATGAACTTTGGGTGAACTAATTTGTCTG-3Ј; and the reverse primer 5Ј-GAAAGCTTGGCACGCTTCAGCCTC-CCGCG-3Ј. After digestion of the PCR products with BglII and HindIII, the fragments were isolated and ligated into the pGL3 Basic Luciferase reporter vector (Promega Corp.), digested with the same restriction enzymes. The mutant promoter constructs were generated by replacing the ApaI (Ϫ139)/HindIII (pGL3B) fragment of the wild-type reporter plasmid with PCR fragments containing the selected mutations. The oligonucleotides used to generate these mutations are the forward primers: P450-RARE-mut, 5Ј-CAGGGGC-CCGATCCGCAATTAAAGAGCTACTTTGGG ACTACTAATTT-GTCTG-3Ј; P450RAI-5-TAAT-mut, 5Ј-CAGGGGCCCGATCC GCAAGTAAAGATGAACTTTGGGTGAACTAATTTGTCTGTTG-TCTG-3Ј; P450RAI-3-TAAT-mut, 5Ј-CAGGGGCCCGATCCG-CAATTAAAGATGAACTT TGGGTGAACTACTTTGTCTG; and the same reverse primer indicated above. All constructs used in transfection experiments were confirmed by sequencing and purified using cesium chloride gradient separation.
Cell Culture and Transient Transfection
The human cervical carcinoma cell line HeLa, the SV40-transformed African green monkey kidney Cos-1 cell line, and the murine embryonical carcinoma F9 wild-type cells and F9 cells in which the RAR␥ and RXR␣ genes had been ablated by homologous recombination, were cultured in an atmosphere of 5% CO 2 at 37 C. HeLa and Cos-1 cells were cultured in MEM, pH 7.3, supplemented with 0.22% sodium hydrogen carbonate,10% FCS, 0.5% penicillin-streptomycin, 0.1% gentamicin, and 0.1% fungizone (Life Technologies, Inc., Gaithersburg, MD). Both F9 cell lines were cultured in DMEM, pH 7.3, supplemented with 0.37% NaHCO 3 (sodium hydrogen carbonate), 0.35% dextrose, 10% FCS, 0.5% penicillin-streptomycin, 0.1% gentamicin, and 0.1% fungizone (Life Technologies, Inc.). double knockout cells, were split and 1-2 ϫ 10 5 cells were seeded in 24-well plates coated with 0.1% gelatin. Cells were transfected with 2 g of DNA using the polyethylenimine reagent (PEI; Aldrich Chemical Co., Inc., Milwaukee, WI). We incubated 1 l of PEI (3.5 g/l) in 49 l of sodium chloride (NaCl) at a concentration of 150 mM, and separately 2 g of DNA (1 g/l) with 48 l of NaCl 150 mM, for 5 min at room temperature. The PEI/NaCl mix was added to the DNA/NaCl mix and incubated for 15 min at room temperature. Transfections were performed by addition of the 100 l mix to 200 l of freshly replaced medium for 5 h. Cells were washed with 1ϫPBS and 500 l of medium were added for 19 h. After transfection, cells were treated either with 0.1% of dimethylsulfoxide (DMSO) vehicle or with 10 Ϫ6 M final all-trans retinoic acid in DMSO (RA, Sigma, St. Louis, MO) for 24 h, and proteins were extracted using the passive lysis buffer (Promega Corp.). To normalize the Firefly luciferase activity, cells were cotransfected with 0.2 g of pRL-SV40 per well, a vector expressing the Renilla luciferase gene (Promega Corp.). Cell extract (20 l) was read using both dual luciferase reagents (Promega Corp.) in a 96-well plate in a Berthold Luminometer. All transfections were performed in triplicate, and experiments were repeated three times.
Twenty four hours before transfection, HeLa and Cos-1 cells were split and 3-4 ϫ 10 5 cells were seeded in each well of a six-well plate in 2 ml of culture medium. Two hours before transfection the culture medium was replaced. Transfections of these two cell lines were performed with the FuGENE transfection reagent, according to the manufacturer's instructions (Roche Molecular Biochemicals, Indianapolis, IN). Twenty four hours after transfection, cells were treated either with DMSO or with RA. After 24 h of treatment, cells were washed twice in PBS and harvested in 250 l of passive lysis buffer at 4 C (Promega Corp.). Reading and normalization of the data were performed as described for F9 wild-type cells and F9 RAR␥ Ϫ/Ϫ RXR␣ Ϫ/Ϫ double knockout cells. All transfections were performed in triplicate and repeated three times.
Nuclear Extract Preparation
Nuclear extracts from HeLa cells, Cos-1 cells, F9 wild-type cells, F9 RAR␥ Ϫ/Ϫ RXR␣ Ϫ/Ϫ double knockout cells, and P19 cells were prepared as described by Leggett et al. (43) .
Gel Mobility Shift and Supershift Assays
Gel mobility shift assays corresponding to R1 (see oligonucleotides R1-WT and R1-MT, Fig. 2, A and B) , and for the identification of the Sp1 site, were performed as described by Lichtsteiner et al. (58) , except that the binding reactions were incubated for 15 min on ice before separation on a 6% nondenaturing polyacrylamide gel. Oligonucleotides used in the experiments are shown in the corresponding figures. Double-stranded oligonucleotides (100 ng/l) were separated from single-stranded oligonucleotides by electrophoresis on a 15% nondenaturing polyacrylamide gel. The oligonucleotides corresponding to R1 were end labeled by T4 polynucleotide kinase using 3 l of 10 Ci/l (␥Ϫ 32 P) dATP and purified on a G-50 Sephadex column. Oligonucleotides corresponding to GGRE (guanine-guanine-rich element) were annealed and radiolabeled (300 ng) by the fill-in reaction with Klenow DNA polymerase and (␣Ϫ 32 P) dATP (New England Biolabs, Inc., Beverly, MA). The sequence of the CSp1 oligonucleotide corresponds to the Sp1-SV40 consensus described by Leggett et al. (43) .
Supershift experiments were carried out using monoclonal RXR (m-␣, ␤, ␥) (59) and purified polyclonal Sp1 (PEP) and Sp3 (D20)-G rabbit antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). For each reaction, 1 l of antibody anti-RXR and 1.5 l of antibody anti-Sp1 and -Sp3 were preincubated with 5 l of the F9 and P19 protein extracts in the bandshift binding reaction for 20 min on ice. Oligonucleotides (200,000 cpm) were added to the reaction and incubated for 15 min on ice before separation on a nondenaturing 6%, 0.25ϫTBE polyacrylamide gel.
In Vitro Transcription and Translation
Twenty micrograms of each of the expression plasmids containing RAR␥ and RXR␣ were linearized by digestion at 37 C using the XhoI restriction enzyme. The DNA was precipitated by addition of 0.3 volumes of 3 M sodium acetate, pH 7.0, and 2 volumes of ethanol. Pellets were dried and resuspended in 20 l nuclease free water. The in vitro transcription and translation were performed using the TNT T7/T3 Coupled Reticulocyte Lysate System kit (Promega Corp.) according to procedures suggested by the manufacturer.
Northern Blot Analysis
To determine P450RAI inducibility by RA in mouse liver, C-57 black mice were treated with 100 mg/kg RA in a DMSO/cornoil carrier mixture. Control mice were treated with the DMSO/ corn-oil carrier mixture alone. After 2, 8, and 24 h of treatment, mice were killed by cervical dislocation and livers were immediately excised. Livers were first snap-frozen in liquid nitrogen and then homogenized in 15 ml of TRIzol (Life Technologies, Inc.) for 20 min. Samples were spun down at 6,000 rpm for 20 min at 4 C, and the supernatants were then used to extract RNA as described by Abu-Abed et al. (26) . Northern blot analyses were also performed using probes for P450RAI and the control probe 36B4 as described by Abu-Abed et al. (26) .
DNase I Footprint Analysis
Liver tissue nuclear extracts were prepared from 6-to 12-week-old C-57 black mice as described by Sierra et al. (60) . Tissue was homogenized (1.5 g/10 ml) using a machine-driven Teflon pestle homogenizer in 10 mM HEPES, pH 7.6, 12 mM KCl, 0.15 mM spermine, 0.5 mM spermidine, 1 mM EDTA, 2.2 M sucrose, 5% glycerol, 1% skim milk, 0.5 mM dithiothreitol (DTT), 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 14 g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml pepstatin A, and 1 mM benzamidine. The homogenate was layered onto 10-ml pads of the same buffer (without milk), and the nuclei were pelleted by centrifugation at 24,000 rpm for 60 min in a SW-28 rotor. The clean nuclei were resuspended in 10 ml nuclear lysis buffer (10 mM HEPES, pH 7.6, 100 mM KCl, 0.1 mM EDTA, 10% glycerol, 3 mM MgCl 2 , 1 mM DTT, 0.1 mM PMSF, and 14 g/ml aprotinin). Nuclei were lysed with KCl (0.55 M final) and were centrifuged at 40,000 rpm in a Ti-50 rotor for 60 min. The supernatant was then transferred to a clean tube. Solid (NH 4 ) 2 SO 4 was added to 0.3 g/ml. The mixture was incubated in ice water for 60 min and then centrifuged at 40,000 rpm in a Ti-50 rotor for 20 min. The pellet was resuspended in nuclear dialysis buffer (25 mM HEPES, pH 7.6, 40 mM KCl, 0.1 mM EDTA, 10% glycerol, and 1 mM DTT) and dialyzed twice against the same buffer for 2 h each time. The DNase I footprinting reactions were performed as described by Sierra et al. (61) . P450RAI promoter fragment were directionally end labeled after digestion by either AvrII (noncoding strand) or NcoI (coding strand) and filled-in by Klenow DNA polymerase (New England Biolabs, Inc.) with dCTP, dGTP, dTTP, and (␣Ϫ 32 P) dATP. The labeled DNA was digested with second enzymes to generate approximately 300-bp fragments that spanned the proximal promoter region. The binding reactions (in 40 l) were performed in footprinting buffer (37.5 mM HEPES, pH 7.6, 54 mM KCl, 0.05 mM EDTA, 5% glycerol, 5 mM MgCl 2 , and 0.5 mM DTT) containing 40,000 cpm of probe, 2 g poly dI⅐dC, and between 5 and 90 g of liver or testes nuclear extracts or 10 g BSA for control DNA. The reactions were incubated on ice for 15 min. Three microliters of DNase I (Roche Molecular Biochemicals, Indianapolis, IN) were added (1:40 to 1:30 dilution of 3.3 mg/ml stock solution), and the reactions were allowed to digest on ice for 5 min. Five volumes of stop buffer (20 mM Tris-HCl, pH 8.0, 20 mM EDTA, 250 mM NaCl, 0.5% SDS, 1 mg/ml Proteinase K, and 0.0025 mg/ml sheared salmon sperm DNA) were added, and the reactions were incubated at 50 C for 60 min. The DNA was extracted twice with phenol-chloroform and ethanol precipitated. Chemical cleavage reactions were performed as described by Sambrook et al. (62) . Products were dissolved in formamide loading buffer, separated on a denaturing 6 M urea 6% polyacrylamide gel, and visualized by autoradiography.
